Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.32 (market cap $2.27B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 7.5× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| SLS | ZBH | |
|---|---|---|
Market Cap | $2.27B | $16.95B |
Volume | 4,179,659 | 2,505,240 |
Sector | Health | Health |
52-Week High | $15.46 | $103.98 |
52-Week Low | $1.39 | $79.58 |
Enterprise Value | $2.14B | $24.02B |
Typical Hold Time | — | 89 Days |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
